<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01692041</url>
  </required_header>
  <id_info>
    <org_study_id>HeHe</org_study_id>
    <nct_id>NCT01692041</nct_id>
  </id_info>
  <brief_title>Effect of an add-on Treatment With Ivy Leaves Dry Extract on Lung Function in Bronchial Asthma</brief_title>
  <acronym>HeHe</acronym>
  <official_title>Tolerance and Effect of an add-on Treatment With a Cough Medicine Containing Ivy Leaves Dry Extract on Lung Function in Children With Bronchial Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Technische Universität Dresden</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Technische Universität Dresden</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The trial aims to record possible effects of a supplementary treatment with ivy leaves dry
      extract on different lung function parameter, on bronchial hyperreactivity, on individual
      markers of asthmatic inflammation and on the clinical symptom profile. The hypothesis is,
      that the additional therapy might improve these parameters and might help to optimize asthma
      therapy.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2012</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MEF75-25 before bronchodilation - relative change</measure>
    <time_frame>every 4 weeks</time_frame>
    <description>MEF75-25 will be measured at every time point of the study and relative changes will be followed</description>
  </primary_outcome>
  <primary_outcome>
    <measure>FEV1 before bronchodilation - relative change</measure>
    <time_frame>every 4 weeks</time_frame>
    <description>FEV1 before bronchodilation will be measured at every study visit and changes will be documented</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>MEF75-25 before bronchodilation - absolute change</measure>
    <time_frame>every 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1 before bronchodilation - absolute change</measure>
    <time_frame>every 4 weeks</time_frame>
    <description>FEV1 before bronchodilation will be measured every visit and changes documented</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Emergency treatment (beta agonist demand)</measure>
    <time_frame>daily</time_frame>
    <description>Emergency treatment (beta agonist demand)will be documented daily at home and checked at every study visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days with asthma symptoms</measure>
    <time_frame>daily</time_frame>
    <description>Number of days with asthma symptoms will be documented daily and checked at every study visit.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Ivy leave</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>active therapy arm with Ivy leave 5 ml twice daily p.o. for four weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Ivy leave placebo 5 ml twice daily p.o. for four weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ivy leaves dry extract</intervention_name>
    <description>5 ml twice daily po</description>
    <arm_group_label>Ivy leave</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>5 ml per os twice daily</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Medical diagnosis of uncontrolled, mild, persistent, allergic bronchial asthma in
             terms of the bronchial asthma NVL Version 1.3 (2011)

          2. Children aged from 6 to 12 years (girls and boys)

          3. Signed Informed Consent of the patient and his legal guardians to participate in the
             trial after written and verbal briefing by the Investigator

          4. Improvement of the FEV1≥12% after 2 puffs of terbutaline 100 µg dur-ing steroid
             monotherapy with 400 µg budesonide equivalent/day or an ACT score ≤ 19 as an
             indication of insufficient asthma control

          5. Asthma diagnosis for at least 1 year

        Exclusion Criteria:

          1. Anamnestically known intolerance/allergy to one of the drugs applied or to their
             ingredients or to drugs of similar chemical structure

          2. Participation of the patient in another clinical trial within the last four weeks
             before enrollment in this trial

          3. Evidence suggesting that the patient or their legal representative is not likely to
             follow the trial protocol (e.g. lacking compliance)

          4. Inability to measure lung function, to test bronchospasmolysis, to determine FeNO or
             to collect exhaled breath condensate, inability to document the symptoms in a symptom
             log book or questionnaire; in-ability to take the trial medication properly

          5. Chronic illnesses of different aetiology

          6. Vocal cord dysfunction

          7. Premature birth or diagnosis of bronchopulmonary dysplasia

          8. Gastroesophageal reflux

          9. Acute respiratory infection within the previous 4 weeks

         10. Hereditary fructose intolerance

         11. Pregnant or breastfeeding girls -
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Christian Vogelberg, MD PhD</last_name>
    <phone>0049 351 458 2073</phone>
    <email>christian.vogelberg@uniklinikum-dresden.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Universitätsklinikum Carl Gustav Carus, Kinderklinik</name>
      <address>
        <city>Dresden</city>
        <state>Saxonia</state>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian Vogelberg, MD PhD</last_name>
      <phone>0049 351 458</phone>
      <phone_ext>2073</phone_ext>
      <email>christian.vogelberg@uniklinikum-dresden.de</email>
    </contact>
    <investigator>
      <last_name>Christian Vogelberg, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sabine Zeil, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 3, 2012</study_first_submitted>
  <study_first_submitted_qc>September 24, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 25, 2012</study_first_posted>
  <last_update_submitted>September 24, 2012</last_update_submitted>
  <last_update_submitted_qc>September 24, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 25, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>asthma</keyword>
  <keyword>children</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

